Top

Annals of Hematology

Published in:

01-04-2018 | Letter to the Editor

The Deauville criteria cannot differentiate between responding and non-responding non-Hodgkin lymphoma patients

Authors: Hugo J. A. Adams, Thomas C. Kwee

Published in: Annals of Hematology | Issue 4/2018

Excerpt

Dear Editor, …

Barrington SF, Johnson PW (2017) FDG PET-CT in lymphoma: has imaging-directed personalized medicine become a reality? J Nucl Med 58(10):1539–1544. https://doi.org/10.2967/jnumed.116.181347 CrossRefPubMed

Yamane T, Daimaru O, Ito S, Yoshiya K, Nagata T, Ito S, Uchida H (2004) Decreased 18F-FDG uptake 1 day after initiation of chemotherapy for malignant lymphomas. J Nucl Med 45(11):1838–1842PubMed

Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T (1992) Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 33(11):1972–1980PubMed

Brepoels L, Stroobants S, Verhoef G, De Groot T, Mortelmans L, De Wolf-Peeters C (2009) (18)F-FDG and (18)F-FLT uptake early after cyclophosphamide and mTOR inhibition in an experimental lymphoma model. J Nucl Med 50(7):1102–1109. https://doi.org/10.2967/jnumed.109.062208 CrossRefPubMed

Brepoels L, De Saint-Hubert M, Stroobants S, Verhoef G, Balzarini J, Mortelmans L, Mottaghy FM (2010) Dose-response relationship in cyclophosphamide-treated B-cell lymphoma xenografts monitored with [18F]FDG PET. Eur J Nucl Med Mol Imaging 37(9):1688–1695. https://doi.org/10.1007/s00259-010-1479-0 CrossRefPubMed

Moskowitz CH, Schoder H, Teruya-Feldstein J, Sima C, Iasonos A, Portlock CS, Straus D, Noy A, Palomba ML, O'Connor OA, Horwitz S, Weaver SA, Meikle JL, Filippa DA, Caravelli JF, Hamlin PA, Zelenetz AD (2010) Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in advanced-stage diffuse large B-cell lymphoma. J Clin Oncol 28(11):1896–1903. https://doi.org/10.1200/JCO.2009.26.5942 CrossRefPubMedPubMedCentral

Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V, International Harmonization Project on L (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25(5):579–586. https://doi.org/10.1200/JCO.2006.09.2403 CrossRefPubMed

Casasnovas RO, Meignan M, Berriolo-Riedinger A, Bardet S, Julian A, Thieblemont C, Vera P, Bologna S, Briere J, Jais JP, Haioun C, Coiffier B, Morschhauser F, Groupe d'etude des lymphomes de la (2011) SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma. Blood 118(1):37–43. https://doi.org/10.1182/blood-2010-12-327767 CrossRefPubMed

Cox MC, Ambrogi V, Lanni V, Cavalieri E, Pelliccia S, Scopinaro F, Monarca B, Marchetti P, Spiriti MA (2012) Use of interim [18F]fluorodeoxyglucose-positron emission tomography is not justified in diffuse large B-cell lymphoma during first-line immunochemotherapy. Leuk Lymphoma 53(2):263–269. https://doi.org/10.3109/10428194.2011.614704 CrossRefPubMed

10.

Schoder H, Zelenetz AD, Hamlin P, Gavane S, Horwitz S, Matasar M, Moskowitz A, Noy A, Palomba L, Portlock C, Straus D, Grewal R, Migliacci JC, Larson SM, Moskowitz CH (2016) Prospective study of 3′-Deoxy-3'-18F-Fluorothymidine PET for early interim response assessment in advanced-stage B-cell lymphoma. J Nucl Med 57(5):728–734. https://doi.org/10.2967/jnumed.115.166769 CrossRefPubMed

Title: The Deauville criteria cannot differentiate between responding and non-responding non-Hodgkin lymphoma patients
Authors: Hugo J. A. Adams
Thomas C. Kwee
Publication date: 01-04-2018
Publisher: Springer Berlin Heidelberg
Published in: Annals of Hematology / Issue 4/2018
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-017-3202-8

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

The Deauville criteria cannot differentiate between responding and non-responding non-Hodgkin lymphoma patients

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 4/2018

Outcomes of previously untreated elderly patients with AML: a propensity score-matched comparison of clofarabine vs. FLAG

Further classification of neutrophil non-muscle myosin heavy chain-IIA localization for efficient genetic diagnosis of MYH9 disorders

MRD-negative complete remission in relapsed refractory hairy cell leukemia with bendamustine and obinutuzumab

Non-severe form of severe fever with thrombocytopenia syndrome (SFTS)

A novel heterozygous ITGB3 p.T720del inducing spontaneous activation of integrin αIIbβ3 in autosomal dominant macrothrombocytopenia with aggregation dysfunction

Efficacy of antithymocyte globulin as first-line treatment for aplastic anemia—a single-center experience

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page